Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Argus Health
Merck
Harvard Business School
Federal Trade Commission

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,417,175

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,417,175 protect, and when does it expire?

Patent 6,417,175 protects TEFLARO and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 6,417,175
Title: Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Abstract:A novel cephem compound of the formula: ##STR1## wherein R.sup.1 is a phosphono group or a group convertible to a phosphono group; R.sup.2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH.sub.2 ; n is 0 or 1; one of R.sup.3 and R.sup.4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R.sup.3 and R.sup.4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
Inventor(s): Ishikawa; Tomoyasu (Otsu, JP), Hashiguchi; Shohei (Toyonaka, JP), Iizawa; Yuji (Muko, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/555,949
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,417,175
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,417,175

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-001 Oct 29, 2010 RX Yes No   Try a Free Trial   Try a Free Trial Y Y METHODS FOR TREATING BACTERIAL INFECTIONS   Try a Free Trial
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-002 Oct 29, 2010 RX Yes Yes   Try a Free Trial   Try a Free Trial Y Y METHODS FOR TREATING BACTERIAL INFECTIONS   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,417,175

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-351499Dec 19, 1997
PCT Information
PCT FiledDecember 17, 1998PCT Application Number:PCT/JP98/05709
PCT Publication Date:July 01, 1999PCT Publication Number: WO99/32497

International Family Members for US Patent 6,417,175

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 430155   Try a Free Trial
Australia 1683299   Try a Free Trial
Canada 2314564   Try a Free Trial
China 1194980   Try a Free Trial
China 1282335   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Queensland Health
US Army
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.